Nintedanib Stada

Nintedanib, the active ingredient in Nintedanib Stada, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and in combination therapy for non‑small cell lung cancer. GNH USA supplies Nintedanib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide across multiple regions, ensuring quality and regulatory compliance.

Nintedanib is used to target fibrotic lung disease pathways and certain oncologic indications. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening. - Non‑small cell lung cancer (in combination therapy): enhances treatment efficacy when combined with chemotherapy.

Nintedanib may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may be transient. - Decreased appetite: reduced desire to eat. - Liver enzyme elevation: mild increase in ALT/AST. Serious or Rare Side Effects: - Severe liver injury: marked transaminase rise or hepatitis. - Gastrointestinal perforation: rare but serious. - Hemorrhage: increased risk of bleeding.

When prescribing Nintedanib Stada, clinicians should consider several safety measures. - Monitor liver function: perform baseline and periodic ALT/AST tests. - Assess for gastrointestinal disorders: evaluate history of ulcer or perforation. - Evaluate bleeding risk: caution in patients on anticoagulants. - Pregnancy and lactation: avoid use as safety is unknown. - Dose adjustments: consider renal or hepatic impairment per prescriber guidance. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Nintedanib Stada interacts with several drug classes that may require avoidance or close monitoring. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - P‑glycoprotein inhibitors (e.g., verapamil): can raise plasma levels. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding. - NSAIDs: increase gastrointestinal adverse events.